Context: Osteoporosis (OP) is a disease of skeletal system and is associated with fragility
fracture at the hip, spine and wrist. Various drugs have been used to treat OP. One of them is …

Osteoporosis (OP), is a systemic bone disorder associated with low bone mass and bone
tissue corrosion. Worsening of the disease condition leads to bone delicacy and fracture …

Owing to its versatility and superiority, nanotechnology-mediated interventions have gained
remarkable recognition. The present study was aimed for efficient co-delivery raloxifene …

Raloxifene (RLX) is a second-generation selective estrogen receptor modulator used to treat
osteoporosis in postmenopausal women. RLX fails to be developed into injectable dosage …

Raloxifene HCl (RH) has poor water solubility and due to its extensive first pass metabolism;
its bioavailability is only 2%. The purpose of the present study was to enhance the aqueous …

Osteoporosis is a disease that reduces bone mass and microarchitecture, which makes
bones fragile. Postmenopausal osteoporosis occurs due to estrogen deficiency. Raloxifene …

Abstract Raloxifene hydrochloride (R-HCl), a BCS class II drug, remains a mainstay in the
prevention and pharmacologic therapy of osteoporosis. Its absolute bioavailability, however …

Purpose In the clinical setting, raloxifene, a second-generation selective estrogen receptor
modulator, is administered orally; however, the bioavailability (BA) is only 2% because of its …

Objective: Raloxifene hydrochloride (RLX) is widely used in the treatment of osteoporosis,
but due to its extensive first pass metabolism bioavailability of RLX is remaining only 2%. In …

Context: Osteoporosis (OP) is the most common metabolic bone disease predominantly
found in elderly people. It is associated with reduced bone mineral density, results in a …